The tweet was deleted by the author.
But we saved everything 🙂.
Olema Pharmaceuticals highlighted its participation in the European Society for Medical Oncology Congress 2025.
The company engaged in scientific exchange, focusing on future advancements in oncology research and treatment. The event, known for showcasing key developments in medical science, provided a platform for Olema Pharmaceuticals to share its innovative strategies in the field of cancer research.
The company expressed gratitude to its team members for their active involvement, underlining their commitment to pioneering new solutions in oncology.
Olema Pharmaceuticals' engagement at ESMO25 further builds upon its momentum in cancer research, following the recent presentation of new palazestrant data that underscored the company’s commitment to advancing oncology innovation. For additional context on Olema’s latest breakthroughs, see the unveiling of pivotal findings on palazestrant at ESMO25, which highlighted the potential impact of these developments on future treatment paradigms.